Literature DB >> 11843379

Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age.

N J Sebire1, M Foskett, R A Fisher, H Rees, M Seckl, E Newlands.   

Abstract

All cases of first histologically confirmed complete and partial moles registered between 1985 and 1999 were identified from the database of a Trophoblastic Disease Registration Centre. The maternal age distribution at diagnosis was calculated for the 7916 molar pregnancies and compared with the maternal age distribution of an unselected population of women from a routine obstetric database. Likelihood ratios were calculated for complete and partial molar pregnancies by maternal age. A positive relationship was found between the risk of molar pregnancy and both upper and lower extremes of maternal age (> or = 45 years and < or = 15 years, respectively). This association, although present for both complete and partial moles, is much greater for complete mole at all maternal ages, and the degree of risk is much greater with older (> or = 45 years) rather than younger (< or = 15 years) maternal age. This study provides, for the first time, data regarding specific risk of partial versus complete hydatidiform mole with maternal age.

Entities:  

Mesh:

Year:  2002        PMID: 11843379     DOI: 10.1111/j.1471-0528.2002.t01-1-01037.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  23 in total

1.  Puerperal choriocarcinoma.

Authors:  L Beavington; M Mossa
Journal:  BMJ Case Rep       Date:  2011-02-02

Review 2.  The hydatidiform mole.

Authors:  Jean-Jacques Candelier
Journal:  Cell Adh Migr       Date:  2015-09-30       Impact factor: 3.405

Review 3.  Gestational trophoblastic tumours: an update for 2014.

Authors:  Fieke E M Froeling; Michael J Seckl
Journal:  Curr Oncol Rep       Date:  2014-11       Impact factor: 5.075

4.  Hydatidiform moles among patients with incomplete abortion in Mwanza City, North western Tanzania.

Authors:  Bernard Kitange; Dismas Matovelo; Eveline Konje; Anthony Massinde; Peter Rambau
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

5.  Massive fetomaternal hemorrhage caused by an intraplacental choriocarcinoma: a case report.

Authors:  Anna-Karina Aaris Henningsen; Lisa Leth Maroun; Hanne Havsteen; Jens Svare
Journal:  Case Rep Med       Date:  2010-03-03

Review 6.  Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia.

Authors:  Mo'iad Alazzam; John Tidy; Raymond Osborne; Robert Coleman; Barry W Hancock; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2016-01-13

7.  Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes.

Authors:  Yassemine Khawajkie; Nawel Mechtouf; Ngoc Minh Phuong Nguyen; Kurosh Rahimi; Magali Breguet; Jocelyne Arseneau; Brigitte M Ronnett; Lori Hoffner; Felicia Lazure; Marjolaine Arnaud; Fabrice Peers; Liane Tan; Basam Abu Rafea; Monica Aguinaga; Neil S Horowitz; Asangla Ao; Seang Lin Tan; Richard Brown; William Buckett; Urvashi Surti; Karine Hovanes; Trilochan Sahoo; Philippe Sauthier; Rima Slim
Journal:  Mod Pathol       Date:  2019-12-19       Impact factor: 7.842

8.  Ultrasound diagnosis of molar pregnancy.

Authors:  Jackie A Ross; Alina Unipan; Jackie Clarke; Catherine Magee; Jemma Johns
Journal:  Ultrasound       Date:  2018-03-02

9.  Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset.

Authors:  Y K Eysbouts; P B Ottevanger; L F A G Massuger; J IntHout; D Short; R Harvey; B Kaur; N J Sebire; N Sarwar; F C G J Sweep; M J Seckl
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

10.  Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases.

Authors:  Deyin Xing; Emily Adams; Jialing Huang; Brigitte M Ronnett
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.